![]() ![]() Typically, the director follows her committee’s decision, though she doesn’t have to. ![]() It will also include a discussion of clinical considerations for administering the shot, which consists of two injections three weeks apart.Īfter the advisers meet today, CDC director Rochelle Walensky will issue a final say on whether to recommend the vaccine. ![]() EDT time today, will include an update on the number of myocarditis and pericarditis cases resulting from vaccination. The meeting, scheduled to begin at 10 a.m. It’s an older technology than what’s used in the Pfizer-BioNTech and Moderna vaccines, which Novavax executives hope will appeal to the roughly 10 percent of U.S. The vaccine, authorized by the Food and Drug Administration last week, was more than 90 percent effective in clinical trials and contains a version of the coronavirus spike protein made with moth cells. | Carsten Koall/Getty ImagesĬDC ADVISERS TO DISCUSS NOVAVAX VACCINE - The Centers for Disease Control and Prevention’s external advisory committee will meet today to discuss Novavax’s Covid-19 vaccine for adults who haven’t yet been immunized. ![]() The CDC's advisory committee meets today to consider whether Novavax's Covid-19 vaccine should be approved for adults who haven't been immunized. “There seems to be hesitation to do anything that could limit innovation of new products, which is what action related to launch prices would do,” he said. Lawmakers have introduced bills in the past to address high drug-launch prices, Meekins said, so the absence of any mention of them in the reconciliation language likely means not enough Democrats would support such a change. That means drug companies could still set high prices when a drug enters the market, taking into account limited returns in later years once the drug is subject to Medicare negotiation, he said. “There will be savings to the government on one side of the ledger, but the pharmaceutical companies have a path to make up that revenue loss by just increasing launch prices, and there’s nothing in this bill that limits that,” said Chris Meekins, a former HHS and Hill adviser who’s now a health policy analyst at Raymond James. But an analyst says what’s not in the bill could be a big win for industry. What does this mean for pharma? Politically, getting language blessed by both the Senate parliamentarian and West Virginia Democrat Joe Manchin and passed through Congress would be a win for Democrats heading into the midterms since it would hand the party a legislative win before what are most likely to be next month’s ugly inflation figures. Meanwhile, Republicans are preparing their own procedural attacks on the already slimmed-down measure, POLITICO’s Caitlin Emma and Jennifer Scholtes write. That will determine whether Democrats can pass the provisions with 51 votes instead of the usual 60. The Senate parliamentarian is expected to hear arguments Thursday on Democrats’ plan to allow Medicare to negotiate drug prices as part of the office’s review to ensure the legislation complies with the Byrd rule, a chamber aide told POLITICO’s Alice Miranda Ollstein. RECONCILING WHAT DRUG PRICING MEANS FOR PHARMA - All eyes are on the Senate this week as lawmakers battle over the piece of Democrats’ reconciliation bill that’s still standing as of now: An effort to lower some drug prices that Medicare pays. Democrats want Medicare to have the ability to negotiate drug prices. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |